ANI Return On Equity from 2010 to 2025

ANIP Stock  USD 66.33  0.35  0.53%   
ANI Pharmaceuticals Return On Equity yearly trend continues to be relatively stable with very little volatility. Return On Equity is likely to drop to -0.05. Return On Equity is a measure of the profitability of ANI Pharmaceuticals in relation to the equity, calculated by dividing net income by shareholder's equity. View All Fundamentals
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(0.04)
Current Value
(0.05)
Quarterly Volatility
0.46639702
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 71.1 M, Interest Expense of 18.5 M or Selling General Administrative of 262.1 M, as well as many indicators such as Price To Sales Ratio of 1.65, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Return On Equity Growth Pattern

Below is the plot of the Return On Equity of ANI Pharmaceuticals over the last few years. Return on Equity is the amount of ANI Pharmaceuticals net income returned as a percentage of ANI Pharmaceuticals equity. Return on equity measures ANI Pharmaceuticals profitability by revealing how much profit ANI Pharmaceuticals generates with the money shareholders have invested. It is a measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity. ANI Pharmaceuticals' Return On Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported -0.041810 Years Trend
Slightly volatile
   Return On Equity   
       Timeline  

ANI Return On Equity Regression Statistics

Arithmetic Mean(0.21)
Coefficient Of Variation(222.83)
Mean Deviation0.34
Median(0.01)
Standard Deviation0.47
Sample Variance0.22
Range1.5704
R-Value0.58
Mean Square Error0.16
R-Squared0.33
Significance0.02
Slope0.06
Total Sum of Squares3.26

ANI Return On Equity History

2025 -0.0454
2024 -0.0432
2023 0.041
2022 -0.14
2020 -0.12
2019 0.0286
2018 0.0785

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Return On Equity, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Return On Equity(0.04)(0.05)

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.